RGEN 250117 160.00P (RGEN250117P160000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

RGEN250117P160000

Watchlist

4.00
-4.45-52.66%

15min DelayClose Jan 13 16:00 ET

4.00High4.00Low

Intraday

5D
Daily

News

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswireJan 7 07:30 ET
Repligen Announced The Commercial Launch Of Its CTech SoloVPE PLUS System For At-line Ultraviolet-visible Concentration Measurement In Complex Biological Production Workflows, From Process Development Scale Through CGMP Manufacturing
BenzingaJan 6 07:33 ET
Repligen Launches the CTech SoloVPE PLUS System
GlobeNewswireJan 6 07:30 ET
Repligen Corporation (RGEN) Fell Along With Peers
Yahoo FinanceDec 20, 2024 09:21 ET
Repligen Initiated at Hold by Canaccord Genuity
Dow JonesDec 17, 2024 11:09 ET · Ratings
Repligen Analyst Ratings
BenzingaDec 17, 2024 10:57 ET · Ratings

Comments

Moomoo AI

Feb 28, 2024 11:18

Despite a revenue dip, investors bank on Repligen's future growth, justifying a high P/S ratio. Strong revenue forecasts may keep share prices up, unless analysts' predictions are off.

Repligen Corporation's (NASDAQ:RGEN) Popularity With Investors Is Clear

Moomoo AI

Feb 13, 2024 10:54

No recent insider transactions at Repligen isn't concerning, but last year's transactions aren't encouraging. Modest insider ownership suggests alignment with shareholders. However, Repligen has 1 warning sign that shouldn't be ignored.

Repligen Insiders Sold US$1.7m Of Shares Suggesting Hesitancy

Moomoo AI

Dec 19, 2023 08:38

The growth of Repligen parallels investors' sentiment, with EPS growth and yearly share price increases closely matched. Five-year return of 30% suggests consolidation amidst the firm's continued execution of its growth strategy.

Repligen (NASDAQ:RGEN) Jumps 10.0% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns

Moomoo AI

Nov 1, 2023 09:44

Repligen's projected profit growth and evident undervaluation signal a good investment opportunity. The unreflected potential in the share price suggests now is a desirable time to buy.

Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?

Movers and Shakers

Jul 6, 2023 07:50

Columns Today's Pre-Market Stock Movers And Top Ratings: RGEN, FHN, AFRM, AXP and more

Pre-Market Stock Movers
Gapping up
$Meta Platforms (META.US)$ +0.81% (The social media gianted in premarket trading after the launch of Threads, a direct competitor to Twitter. Meta CEO Mark Zuckerberg said on his Threads account early Thursday that 10 million people had signed up for the platform in seven hours after launching.)
$Sweetgreen (SG.US)$ +5.14% (Sweetgreen jumped more than 4% after Bank of America upgraded...